| answer text |
<p>Most new medicines are assessed by the National Institute for Health and Care Excellence
(NICE) which makes recommendations for the National Health Service on whether they
represent a clinically and cost effective use of NHS resources. Since 2016, NICE makes
recommendations for the NHS on all new licensed cancer medicines through its technology
appraisal programme. NHS commissioners are legally required to fund treatments recommended
in NICE technology appraisal guidance.</p><p>NICE has appraised Avastin (bevacizumab)
for use in the treatment of a number of different types of cancer and has unfortunately
not been able to recommend it as a clinically and cost effective use of NHS resources
for any type of cancer at the price offered by the drug company. Avastin is not therefore
routinely funded by the NHS for any licensed indication.</p><p>Avastin is funded as
an off-label treatment for some types of cancer through the Cancer Drugs Fund.</p>
|
 |
